Key result
Antiplatelet agents such as aspirin, clopidogrel, and dipyridamole exert both beneficial and detrimental non-antiplatelet effects mediated through the endothelium, influencing vasodilation, inflammation, and oxidation.
Antiplatelet agents such as aspirin, clopidogrel, ticlopidine, and dipyridamole have pleiotropic effects mediated by the endothelium that may contribute to their clinical benefit in cerebrovascular disease.
Highlights endothelial pleiotropy in cerebrovascular antiplatelet use; hypothesis-generating and requires prospective validation before practice change.
The antiplatelet drugs, commonly used in the prevention and treatment of cerebrovascular disease, possess a number of effects that are independent of direct antiplatelet actions. Beneficial and detrimental effects both occur. The endothelium is an important mediator of these non-antiplatelet effects. We performed a literature search to locate articles related to acetylsalicylic acid (aspirin), clopidogrel, ticlopidine, and dipyridamole and the interactions of these medications with the endothelium. The role of each of the above medications is explored in relation to vasodilation, inflammation, oxidation, platelet-leukocyte interactions, and thrombogenic tendency via platelet-vessel wall interactions.
No takes yet. Share an insight, caveat, or question.
Mateen et al. (2007) conducted a review in Cerebrovascular disease. Antiplatelet agents (aspirin, clopidogrel, ticlopidine, dipyridamole) was evaluated. Antiplatelet agents such as aspirin, clopidogrel, and dipyridamole exert both beneficial and detrimental non-antiplatelet effects mediated through the endothelium, influencing vasodilation, inflammation, and oxidation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: